MyFinsight
Home
Blog
About
Instil Bio, Inc. (TIL)
Instil Bio, Inc. (TIL)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,213K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation
Depreciation
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
In-process research and developm...
Net loss
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Change in fair value of derivative financial instrument
-
-
0
0
Net loss
-4,299
58,977
-13,587
-49,594
Stock-based compensation
1,036
-6,102
1,768
5,319
Non-cash lease expense
26
-143
71
143
Foreign exchange remeasurement loss (gain)
13
-632
-134
637
Impairment of property, plant and equipment and estimated cost to sell, net
181
-16,569
0
16,569
Impairment of right-of-use assets
-
-
0
0
Change in fair value of contingent consideration
-
-
0
0
Depreciation
248
-510
12
510
Restructuring costs
-91
-
0
91
In-process research and development expenses
-10,000
-
0
10,000
Accretion on invested securities
-
-
-111
181
Amortization (accretion) on invested securities
-80
-178
-
-
Non-cash interest expense
193
-405
193
405
Loss on disposals of property and equipment
0
-2
0
0
Prepaid expenses and other current assets
162
3,407
897
-5,830
Other long-term assets
-80
265
-2,787
2,442
Accrued rent receivable
303
-2,789
3,093
-
Accounts payable
0
-247
403
-139
Operating lease liabilities
-75
1,485
-51
-1,510
Long term liabilities
-8
-
-
-
Accrued expenses and other current liabilities
-1,626
1,630
1,592
-3,168
Net cash used in operating activities
-4,642
28,206
-10,557
-18,986
Purchase of marketable securities
17,509
-61,148
6,558
76,907
Maturities of marketable securities
22,800
-88,700
25,000
85,700
Cash received from held for sale assets
0
-423
5
418
Acquired in-process research and development
-
-
10,000
-
Purchase of derivative financial instrument
-
-
0
-
Net cash provided by investing activities
5,291
-17,975
8,447
9,211
Proceeds from at-the-market offering, net of 0.3 million in issuance costs
-6,611
-
0
6,611
Proceeds from exercise of stock options
0
-853
378
475
Loan agreement closing costs
0
-172
0
172
Net cash provided by financing activities
0
-7,292
378
6,914
Net decrease in cash, cash equivalents and restricted cash
649
2,939
-1,732
-2,861
Effect of exchange rate changes on cash, cash equivalents and restricted cash
1
-44
39
-
Cash, cash equivalents and restricted cashbeginning of period
6,081
6,081
10,635
-
Cash, cash equivalents and restricted cashend of period
5,795
5,145
6,081
-
Cash paid for interest
2,748
-
-
-
Noncash increase in operating lease rou assets and lease liabilities resulting from lease modifications
2,213
-
-
-
Issuance costs
400
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$22,800K
(-73.40%↓ Y/Y)
Net cash provided by
investing activities
$5,291K
(-42.56%↓ Y/Y)
Canceled cashflow
$17,509K
Net decrease in
cash, cash...
$649K
(122.68%↑ Y/Y)
Canceled cashflow
$4,642K
Purchase of marketable
securities
$17,509K
(-77.23%↓ Y/Y)
something is missing
$9,909K
Stock-based compensation
$1,036K
(-80.52%↓ Y/Y)
Depreciation
$248K
(-51.37%↓ Y/Y)
Non-cash interest
expense
$193K
(-52.35%↓ Y/Y)
Impairment of property,
plant and equipment...
$181K
(-98.91%↓ Y/Y)
Restructuring costs
-$91K
(-200.00%↓ Y/Y)
Other long-term
assets
-$80K
(-103.28%↓ Y/Y)
Amortization (accretion) on
invested securities
-$80K
Non-cash lease expense
$26K
(-81.82%↓ Y/Y)
Net cash used in
operating activities
-$4,642K
(75.55%↑ Y/Y)
Canceled cashflow
$11,844K
In-process research and
development expenses
-$10,000K
(-200.00%↓ Y/Y)
Net loss
-$4,299K
(91.33%↑ Y/Y)
Accrued expenses and
other current...
-$1,626K
(48.67%↑ Y/Y)
Accrued rent receivable
$303K
Prepaid expenses and
other current assets
$162K
(102.78%↑ Y/Y)
Operating lease
liabilities
-$75K
(95.03%↑ Y/Y)
Foreign exchange
remeasurement loss (gain)
$13K
(-97.96%↓ Y/Y)
Long term
liabilities
-$8K
Buy us a coffee